Literature DB >> 8891158

Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex.

L M Shah1, S C Meyer, M H Cynamon.   

Abstract

The in vitro activities of pyrimethamine and dapsone alone and in combination were evaluated against 23 clinical isolates of Mycobacterium avium complex. The broth dilution MICs of dapsone and pyrimethamine alone ranged from 16 to > 64 micrograms/ml. Pyrimethamine in combination with a fixed concentration of dapsone at 0.5 microgram/ml showed enhanced activity, with an MIC range of 0.5 to 16 micrograms/ml.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8891158      PMCID： PMC163548     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.

Authors:  M Opravil; B Joos; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

2.  Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone.

Authors:  M D Edstein; J R Veenendaal; K H Rieckmann
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

3.  Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.

Authors:  M Opravil; B Hirschel; A Lazzarin; A Heald; M Pechère; S Rüttimann; A Iten; J von Overbeck; D Oertle; G Praz
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

4.  Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group.

Authors:  C Leport; G Chêne; P Morlat; B J Luft; F Rousseau; S Pueyo; R Hafner; J Miro; J Aubertin; R Salamon; J L Vildé
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

Review 5.  NIH conference. Recent advances in the management of AIDS-related opportunistic infections.

Authors:  H C Lane; B E Laughon; J Falloon; J A Kovacs; R T Davey; M A Polis; H Masur
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

6.  Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the human immunodeficiency virus.

Authors:  M Opravil; M Pechère; A Lazzarin; A Heald; S Rüttimann; A Iten; H Furrer; D Oertle; G Praz; D A Vuitton
Journal:  Clin Infect Dis       Date:  1995-02       Impact factor: 9.079
  6 in total
  2 in total

1.  In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex.

Authors:  C M Shoen; O Choromanska; R C Reynolds; J R Piper; C A Johnson; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

2.  Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.

Authors:  A'Lissa B Gerum; Jonathan E Ulmer; David P Jacobus; Norman P Jensen; David R Sherman; Carol Hopkins Sibley
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.